Ascentage Pharma
AAPG
12 hedge funds and large institutions have $1.25M invested in Ascentage Pharma in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0.05% less ownership
Funds ownership: 0.1% → 0.05% (-0.05%)
14% less funds holding
Funds holding: 14 → 12 (-2)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
66% less capital invested
Capital invested by funds: $3.69M → $1.25M (-$2.43M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$548K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.78K |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$2.72K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$687 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$196 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$462K |
| 2 |
NIM
NEOS Investment Management
Westport,
Connecticut
|
-$412K |
| 3 |
TE
Tema ETFs
New York
|
-$405K |
| 4 |
AA
ABC Arbitrage
Paris,
France
|
-$204K |
| 5 |
XC
XY Capital
Central,
Hong Kong
|
-$147K |
AAPG Hedge Fund Activity: Q4 2025 in Review
12 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Ascentage Pharma (AAPG) for Q4 2025, worth a combined $1.25M — down 66% from $3.69M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AAPG and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $548K. The largest seller was UBS Group, cutting an estimated $462K.
- 12 institutional investors held Ascentage Pharma (AAPG) as of Q4 2025, down from 14 in Q3 2025.
- Funds reported $1.25M of Ascentage Pharma stock for Q4 2025, down 66% quarter-over-quarter.
- 2 funds opened new Ascentage Pharma positions in Q4 2025 and 3 closed out, a net change of -1 holder.
- The largest Ascentage Pharma buyer in Q4 2025 was Point72 Asset Management, an estimated $548K added.
- The largest Ascentage Pharma seller in Q4 2025 was UBS Group, an estimated $462K sold.
Based on aggregated 13F filings for Q4 2025.